Political and economic uncertainty caused pharma M&A to slacken off in 2016, seeing deal values in the sector falling to $273.7bn from $392.4bn the previous year. While 2016 was far from catastrophic for pharma M&A it failed to reach the all-time highs achieved from the mega-deals in 2015, and the collapse of the $160bn mega-deal between Pfizer and Allergan was just one of the year’s setbacks for the sector.
READ MORE >>Archives
Pharma companies set for another big year for M&A
Posted on February 1, 2017 By
Benchmark International in
Allergan +
Benchmark International +
Chinese M&A +
Deal Making +
Donald Trump +
Genentech +
Merck +
mergers +
Roche +
Schering-Plough +
Shanghai Henlius Biotech +
US +
Acquisitions +
Blog +
China +
Jiangsu Hengrui Medicine +
Mergers and Acquisitions +
Pfizer +
Pharma +
Pharma M&A +
USA +
Wyeth